178 related articles for article (PubMed ID: 26740054)
1. Signaling mechanisms of bortezomib in TRAF3-deficient mouse B lymphoma and human multiple myeloma cells.
Edwards SK; Han Y; Liu Y; Kreider BZ; Liu Y; Grewal S; Desai A; Baron J; Moore CR; Luo C; Xie P
Leuk Res; 2016 Feb; 41():85-95. PubMed ID: 26740054
[TBL] [Abstract][Full Text] [Related]
2. N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma.
Edwards SK; Moore CR; Liu Y; Grewal S; Covey LR; Xie P
BMC Cancer; 2013 Oct; 13():481. PubMed ID: 24131623
[TBL] [Abstract][Full Text] [Related]
3. Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2--implications for a combinatorial treatment.
Fristedt Duvefelt C; Lub S; Agarwal P; Arngården L; Hammarberg A; Maes K; Van Valckenborgh E; Vanderkerken K; Jernberg Wiklund H
Oncotarget; 2015 Aug; 6(24):20621-35. PubMed ID: 26036313
[TBL] [Abstract][Full Text] [Related]
4. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
6. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
[TBL] [Abstract][Full Text] [Related]
7. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.
Arkwright R; Pham TM; Zonder JA; Dou QP
Expert Opin Drug Discov; 2017 Feb; 12(2):225-235. PubMed ID: 27917682
[TBL] [Abstract][Full Text] [Related]
8. Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib.
Zhao Y; Zhang K; Li G; Zhang X; Shi D
PLoS One; 2015; 10(5):e0127334. PubMed ID: 25973846
[TBL] [Abstract][Full Text] [Related]
9. Mutated in colorectal cancer (MCC) is a novel oncogene in B lymphocytes.
Edwards SK; Baron J; Moore CR; Liu Y; Perlman DH; Hart RP; Xie P
J Hematol Oncol; 2014 Sep; 7():56. PubMed ID: 25200342
[TBL] [Abstract][Full Text] [Related]
10. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
11. The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo.
Zhou L; Zhang Y; Leng Y; Dai Y; Kmieciak M; Kramer L; Sharma K; Wang Y; Craun W; Grant S
J Hematol Oncol; 2019 Mar; 12(1):25. PubMed ID: 30845975
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1.
Ri M; Iida S; Ishida T; Ito A; Yano H; Inagaki A; Ding J; Kusumoto S; Komatsu H; Utsunomiya A; Ueda R
Cancer Sci; 2009 Feb; 100(2):341-8. PubMed ID: 19068089
[TBL] [Abstract][Full Text] [Related]
13. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
Zou P; Kawada J; Pesnicak L; Cohen JI
J Virol; 2007 Sep; 81(18):10029-36. PubMed ID: 17626072
[TBL] [Abstract][Full Text] [Related]
15. TRAF3 deficiency promotes metabolic reprogramming in B cells.
Mambetsariev N; Lin WW; Wallis AM; Stunz LL; Bishop GA
Sci Rep; 2016 Oct; 6():35349. PubMed ID: 27752131
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
Xargay-Torrent S; López-Guerra M; Montraveta A; Saborit-Villarroya I; Rosich L; Navarro A; Pérez-Galán P; Roué G; Campo E; Colomer D
Clin Cancer Res; 2013 Feb; 19(3):586-97. PubMed ID: 23231952
[TBL] [Abstract][Full Text] [Related]
17. TRAF2/3 deficient B cells resist DNA damage-induced apoptosis via NF-κB2/XIAP/cIAP2 axis and IAP antagonist sensitizes mutant lymphomas to chemotherapeutic drugs.
Vashisht M; Ge H; John J; McKelvey HA; Chen J; Chen Z; Wang JH
Cell Death Dis; 2023 Sep; 14(9):599. PubMed ID: 37679334
[TBL] [Abstract][Full Text] [Related]
18. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
[TBL] [Abstract][Full Text] [Related]
19. Expression Profiles of the Individual Genes Corresponding to the Genes Generated by Cytotoxicity Experiments with Bortezomib in Multiple Myeloma.
Ghasemi M; Alpsoy S; Türk S; Malkan ÜY; Atakan Ş; Haznedaroğlu İC; Güneş G; Gündüz M; Yılmaz B; Etgül S; Aydın S; Aslan T; Sayınalp N; Aksu S; Demiroğlu H; Özcebe OI; Büyükaşık Y; Göker H
Turk J Haematol; 2016 Dec; 33(4):286-292. PubMed ID: 27095044
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression.
Suk FM; Lin SY; Lin RJ; Hsine YH; Liao YJ; Fang SU; Liang YC
Oncotarget; 2015 Sep; 6(28):25988-6001. PubMed ID: 26317903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]